PURPOSE OF REVIEW: Although increasingly recognized, atypical parkinsonian syndromes remain challenging to diagnose and are underrecognized due to overlap with other parkinsonisms. This article provides a diagnostic approach to atypical parkinsonian syndromes, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies. The goal of this review is to aid the clinician in recognizing key clinical and pathologic features and to raise awareness of recent advances in diagnostics and treatment. RECENT FINDINGS: Diagnostic criteria for atypical parkinsonian syndromes are evolving to encompass increasingly recognized heterogeneity in the presentation of these disorders and information gleamed from clinicopathologic correlations. PSP and CBD in particular now share similar pathologic clinical features and include a number of phenotypic variants. Pathologic diagnoses are increasingly used in clinical practice, and there is frequent reference now by clinicians to tauopathies, including PSP and CBD, and the synucleinopathies, which include MSA and dementia with Lewy bodies (as well as Parkinson disease). Research into biomarkers, including both tissue and imaging modalities and genetics, has the potential to increase disease recognition and make earlier diagnosis and treatment possible. Although novel therapeutics are being studied for atypical parkinsonian syndromes such as PSP, no new breakthrough interventions have emerged for the treatment of PSP, CBD, and MSA. Current therapeutic management for these disorders frequently uses a multidisciplinary team approach. SUMMARY: The approach to atypical parkinsonian syndromes requires recognition of a constellation of overlapping but distinct clinical features that help with identifying and distinguishing them from Parkinson disease and other similar disorders.
PURPOSE OF REVIEW: Although increasingly recognized, atypical parkinsonian syndromes remain challenging to diagnose and are underrecognized due to overlap with other parkinsonisms. This article provides a diagnostic approach to atypical parkinsonian syndromes, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies. The goal of this review is to aid the clinician in recognizing key clinical and pathologic features and to raise awareness of recent advances in diagnostics and treatment. RECENT FINDINGS: Diagnostic criteria for atypical parkinsonian syndromes are evolving to encompass increasingly recognized heterogeneity in the presentation of these disorders and information gleamed from clinicopathologic correlations. PSP and CBD in particular now share similar pathologic clinical features and include a number of phenotypic variants. Pathologic diagnoses are increasingly used in clinical practice, and there is frequent reference now by clinicians to tauopathies, including PSP and CBD, and the synucleinopathies, which include MSA and dementia with Lewy bodies (as well as Parkinson disease). Research into biomarkers, including both tissue and imaging modalities and genetics, has the potential to increase disease recognition and make earlier diagnosis and treatment possible. Although novel therapeutics are being studied for atypical parkinsonian syndromes such as PSP, no new breakthrough interventions have emerged for the treatment of PSP, CBD, and MSA. Current therapeutic management for these disorders frequently uses a multidisciplinary team approach. SUMMARY: The approach to atypical parkinsonian syndromes requires recognition of a constellation of overlapping but distinct clinical features that help with identifying and distinguishing them from Parkinson disease and other similar disorders.
Authors: H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: Martin Köllensperger; Felix Geser; Klaus Seppi; Michaela Stampfer-Kountchev; Martin Sawires; Christoph Scherfler; Sylvia Boesch; Joerg Mueller; Vasiliki Koukouni; Niall Quinn; Maria Teresa Pellecchia; Paolo Barone; Nicole Schimke; Richard Dodel; Wolfgang Oertel; Erik Dupont; Karen Østergaard; Christine Daniels; Günther Deuschl; Tanya Gurevich; Nir Giladi; Miguel Coelho; Cristina Sampaio; Christer Nilsson; Håkan Widner; Francesca Del Sorbo; Alberto Albanese; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Christoph Kamm; Thomas Gasser; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Anette Schrag; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2008-06-15 Impact factor: 10.338
Authors: L Donker Kaat; A J W Boon; A Azmani; W Kamphorst; M M B Breteler; B Anar; P Heutink; J C van Swieten Journal: Neurology Date: 2009-05-20 Impact factor: 9.910
Authors: Melissa E Murray; Naomi Kouri; Wen-Lang Lin; Clifford R Jack; Dennis W Dickson; Prashanthi Vemuri Journal: Alzheimers Res Ther Date: 2014-01-02 Impact factor: 6.982
Authors: Mary E Finger; Lyndsay L Madden; Ihtsham U Haq; Christopher J McLouth; Mustafa S Siddiqui Journal: J Clin Neurosci Date: 2019-04-01 Impact factor: 1.961
Authors: Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang Journal: Neurobiol Aging Date: 2019-01-16 Impact factor: 4.673